VYNE Therapeutics Announces Approval of AMZEEQ® (Minocycline) and ZILXI® (Minocycline) in Chinese Economic Pilot Zone
AMZEEQ and ZILXI were approved for the pilot zone among other innovative dermatology products, said Lele Zhang, CEO of Cutia Therapeutics.
- AMZEEQ and ZILXI were approved for the pilot zone among other innovative dermatology products, said Lele Zhang, CEO of Cutia Therapeutics.
- ZILXI or AMZEEQ should not be used in people who are allergic to ZILXI, AMZEEQ, or any tetracycline medicine.
- ZILXI and AMZEEQ are flammable and fire, flame, and smoking must be avoided when applying and right after applying ZILXI or AMZEEQ.
- For more information about VYNE Therapeutics Inc. or its investigational products, visit www.vynetherapeutics.com or follow VYNE on Twitter.